-
公开(公告)号：US20240428929A1
公开(公告)日：2024-12-26
申请号：US18701806
申请日：2022-10-18
Inventor： Ti BAI , Anjali BALAGOPAL , Dan NGUYEN , Steve JIANG
Abstract: Methods and systems for computer-assisted contour revision. An image slice may be selected from a medical image. The image slice may include an initial contour of a target anatomical structure in the medical image. At least a portion of the image slice and the initial contour may be displayed on a graphical user interface (GUI). Upon determining that the initial contour requires revision, a revised contour may be generated. A first input may be received from a user to the GUI to indicate a first point of revision. The medical image, the first input, and the initial contour may be input into a trained deep neural network that automatically extracts learned image characteristics. The extracted learned image characteristics may be processed using one or more deep-learning segmentation algorithms of the trained deep neural network. The revised contour may be automatically generated using the processed extracted learned image characteristics.
-
公开(公告)号：US20240423968A1
公开(公告)日：2024-12-26
申请号：US18741420
申请日：2024-06-12
Applicant: The Board of Regents of the University of Texas System , The Board of Trustees of Michigan State University
Inventor： Maria Gaczynska , Pawel A. Osmulski , Jetze Tepe
IPC: A61K31/445 , A61K31/40 , A61P21/00
Abstract: The present disclosure relates to compounds that modulate (i.e., regulate) proteasome activity, pharmaceutical compositions containing such compounds, and uses of these compounds and compositions for the treatment of muscle wasting. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
-
公开(公告)号：US20240392001A1
公开(公告)日：2024-11-28
申请号：US18691249
申请日：2022-09-13
Inventor： Zhiqiang AN , Ningyan ZHANG , Peng ZHAO
IPC: C07K16/28
Abstract: Isolated or recombinant anti-LILRB2 monoclonal antibodies are provided. In some embodiments, the antibodies herein can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as Alzheimer's Disease. In further aspects, the LILRB2-binding antibodies can affect cellular signaling mediated through at least the oA and PS-mediated TREM2 and LILRB2 co-ligation signaling pathway and can be used to modulate microglia function.
-
274.发明申请公开(公告)号：US20240376498A1
公开(公告)日：2024-11-14
申请号：US18785836
申请日：2024-07-26
Inventor： Steven J. GRAY , Frances C. SHAFFO
Abstract: The present disclosure provides methods and compositions for the treatment of diseases and genetic disorders linked to SLC6A1 loss and/or misfunction. The methods and compositions of the present disclosure comprise rAAV vectors and rAAV viral vectors comprising transgene nucleic acid molecules comprising nucleic acid sequences encoding for a GAT1 polypeptide.
-
公开(公告)号：US20240374893A1
公开(公告)日：2024-11-14
申请号：US18658986
申请日：2024-05-08
Inventor： Jacob T. ROBINSON , Peter KAN , Joshua CHEN , Abdeali DHULIYAWALLA
Abstract: The present disclosure is directed to neural interface devices and methods that accesses the subarachnoid space to enable minimally invasive modulation and recording of neural structures. Exemplary embodiments may comprise an implantable pulse generator and a microelectrode catheter. In particular embodiments, the microelectrode catheter comprises one or more stimulating and recording electrodes. Exemplary embodiments may also include methods comprising performing a lumbar puncture to access the spinal subarachnoid space and advancing microcatheter through the spinal subarachnoid space.
-
Patent Agency Ranking
276.发明公开公开(公告)号：US20240360100A1
公开(公告)日：2024-10-31
申请号：US18684645
申请日：2022-08-18
Inventor： Jia Zhou , Kathryn A. Cunningham , Noelle C. Anastasio , Andrew A. Bolinger
IPC: C07D401/12 , A61K31/4525 , A61K31/454 , A61K31/4545 , A61K31/496 , A61K31/5377 , A61K31/541 , C07D211/60 , C07D405/12 , C07D413/12 , C07D417/12
CPC classification number: C07D401/12 , A61K31/4525 , A61K31/454 , A61K31/4545 , A61K31/496 , A61K31/5377 , A61K31/541 , C07D211/60 , C07D405/12 , C07D413/12 , C07D417/12
Abstract: Disclosed herein are serotonin (5-hydroxytryptamine) 5-HT2A receptor and/or 5-HT2C receptor allosteric modulators, the preparation thereof and use thereof.
-
277.发明公开公开(公告)号：US20240352106A1
公开(公告)日：2024-10-24
申请号：US18650019
申请日：2024-04-29
Inventor： Nancy MONSON
IPC: C07K16/18 , A61P25/28 , C12N15/113
CPC classification number: C07K16/18 , A61P25/28 , C12N15/113 , C07K2317/21 , C07K2317/56 , C12N2310/11 , C12N2310/14
Abstract: The present disclosure in various aspects provides methods for making pharmaceutical compositions for treating neurodegenerative diseases (e.g., demyelinating diseases), such as but not limited to multiple sclerosis, neuromyelitis optica, and transverse myelitis. The pharmaceutical compositions impact specific antibody-mediated processes involved in the biology of neurodegenerative disease. In certain aspects, the disclosure provides pharmaceutical compositions for treating neurodegenerative disease, which are based on inhibiting the action of pathologic antibodies, or alternatively providing antibodies to stimulate neuroprotection or repair processes.
-
公开(公告)号：US20240336622A1
公开(公告)日：2024-10-10
申请号：US18260653
申请日：2022-01-08
Inventor： Yonghao YU , Tian QIN , Yuanli ZHEN , Peng LI , Chiho KIM , Heping DENG , Hejun DENG
IPC: C07D493/06 , A61K31/365 , A61K31/443 , A61K45/06 , A61P35/00 , C07D307/77
CPC classification number: C07D493/06 , A61K31/365 , A61K31/443 , A61K45/06 , A61P35/00 , C07D307/77
Abstract: Disclosed herein are compounds of the formula (I) or (II) wherein the variables are defined herein. Also provided are methods of manufacturing and pharmaceutical compositions thereof. In some aspects, the compounds and compositions provided herein may be used as PARP1 inhibitors. In some aspects, the present disclosure provides methods wherein the compounds and compositions described herein are used for the treatment of diseases and disorders, such as cancer.
-
公开(公告)号：US20240325315A1
公开(公告)日：2024-10-03
申请号：US18744370
申请日：2024-06-14
Inventor： Daniel J. SIEGWART , Qiang CHENG
IPC: A61K9/51 , A61K48/00 , C12N9/22 , C12N15/11 , C12N15/113
CPC classification number: A61K9/5123 , A61K48/0033 , C12N9/22 , C12N15/11 , C12N15/111 , C12N15/113 , C12N2310/11 , C12N2310/14 , C12N2310/20 , C12N2320/32
Abstract: In some aspects, the present disclosure provides compositions of lipid nanoparticles useful for the delivery of large RNAs including mRNAs. These compositions may include a cationic ionizable lipid, a phospholipid, a PEGylated lipid, and a steroid including using less of a cationic ionizable lipid than compositions with shorter nucleic acids. These compositions may be used to treat a disease or disorder for which the delivery of an mRNA is therapeutically effective.
-
公开(公告)号：US12104181B2
公开(公告)日：2024-10-01
申请号：US17710464
申请日：2022-03-31
Inventor： John W. Schoggins , Wenchun Fan , Daniel J. Siegwart , Qiang Cheng
CPC classification number: C12N9/104 , A61K9/5123 , A61K48/0066 , A61P31/14
Abstract: Embodiments of the instant disclosure relate to novel antiviral compositions and methods for treating viral infections. In accordance with these embodiments, antiviral compositions can include at least one mRNA encoding for a TRIM7 protein encapsulated into a lipid nanoparticle (LNP). In other embodiments, methods of making antiviral compositions are disclosed as well as methods of administering a composition having at least one mRNA encoding for a TRIM7 protein encapsulated into LNP into a subject.
-
-
-
-
-
-
-
-
-
Search Results
1244
records
(took 0.041 seconds)
